Proposed Allosteric Inhibition of Cyclin-Dependent Kinase 4 by a Proline-Derived Acylsemicarbazide Compound with
Xu Huang1,2, Qingyang Nian1,2, Xizhe Sun1
1Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, School of Pharmacy, Hainan Medical University, Haikou 571199, China.
Abstract:
Background: Cyclin-dependent kinase 4 (CDK4) is a key regulator of cell-cycle progression and an established therapeutic target for breast cancer. Although the unique architecture of its ATP-binding site has enabled the development of highly selective inhibitors, the emergence of acquired resistance highlights the need for alternative therapeutic strategies targeting protein conformational regulation. Methods: The conformational landscape of CDK4 was investigated in this study using accelerated molecular dynamics (aMD) simulations combined with Markov state model (MSM) analysis to identify cryptic conformational states and potential allosteric binding sites. Particular attention was given to the glycine-rich loop (G-loop), a critical structural element that shapes the ATP-binding pocket, and to the effects of compound 8i (1-(2-(3-chlorobenzoyl)hydrazine-1- carbonyl)-N-(pyridin-3-yl)pyrrolidine-2-carboxamide), previously synthesized in our laboratory, on CDK4 dynamics. Results: A distinct conformational transition was identified in which the G-loop shifted toward the N-terminus, resulting in the exposure of a previously unrecognized allosteric pocket adjacent to the catalytic site. Compound 8i interacted with Leu147 and was associated with stabilization of conformational states that favor exposure of the cryptic pocket. Conclusions: These observations suggest that ligand binding may modulate the conformational landscape of CDK4 and favor formation of a cryptic pocket with potential allosteric characteristics. The identified conformational mechanism provides new insights into the dynamic regulation of CDK4 and suggests that stabilization of transient allosteric states represents a promising strategy for the rational design of next-generation CDK4 inhibitors with the potential to overcome resistance in breast cancer therapy.
More Related Videos
11:13Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Positive Regulator Molecules
Positive Regulator Molecules
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anaphase Promoting Complex
